Received Nov 27, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMRV | MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) | MERCK & CO. INC. | UNK | Y019172 | OT |
| MMRV | MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) | MERCK & CO. INC. | UNK | — | OT |
Nurse confirmed reactions; PROQUAD vaccine was being administered by subcutaneous injection but the patient moved during that administration which resulted in half of the vaccine being administered intradermally and half was administered subcutaneously; This Spontaneous report was received from Nurse Practitioner (L.P.N.) and refers to a patient of unknown age and gender. The patient's medical history was not reported. The patient's past medications were not reported. The patient's concomitant medications were not reported. On 10-Nov-2025, patient was vaccinated with Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live lyophilisate (PROQUAD) 0.5 ml, Lot Number: Y019172, Expiration date: 18-May-2026 with sterile diluent for prophylaxis. The vaccine was being administered by subcutaneous injection but the patient moved during that administration which resulted in half of the vaccine being administered intradermally and half was administered subcutaneously (inappropriate route off product administration). Nurse confirmed reactions (nonspecific reaction). No more details were provided. The outcome of nonspecific reaction was not provided. The causality between the event and Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live lyophilisate (PROQUAD) was not reported.